Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy

Updated results of the KATHERINE trial, which evaluated adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab in patients with HER2+ early breast cancer with residual invasive disease in the breast or axillary lymph nodes after receiving neoadjuvant therapy.  According to the researchers, these 8-year updated results strengthen the clinically meaningful benefit from T-DM1, although larger studies are needed.